Work

[CLAG±DAC regimen in the treatment of refractory/relapsed acute myeloid leukemia].

Year: 2024

Type: other

Abstract: The CLAG±DAC regimen is considered effective in patients with R/R AML, whereas decitabine combined with the CLAG regimen is more suitable for patients with R/R AML combined with FLT3-ITD mutation.

Source: PubMed

DOI: 10.3760/cma.j.cn121090-20240604-00203

Authors: W X Hua, W Q Yao, M Zhou, J Q Qi, H Z Kang, R J Wang, C S Cai, Y J Liu, D P Wu, Y Han

Institution: First Affiliated Hospital of Soochow University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Natural Science Foundation of China

Award: G2726921906

OpenAlex ID: W4403515970

Cites: 1

Cited by: 1

Related to: 10